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Introduction
During sepsis, lipopolysaccharide (LPS) and other pathogen lipids are sequestered within lipoprotein fractions (HDL, LDL and VLDL). HDL can neutralize the inflammatory effects of LPS and potentially increase LPS clearance [1] . Amongst the lipoprotein fractions, HDL may have the highest affinity for LPS [2] and other pathogen lipids [3] is associated with anti-inflammatory [4, 5] , anti-apoptotic [6] , anti-thrombotic [7] and endothelial protective properties [8] . In particular, the administration of Apo A-I mimetic peptides in sepsis was associated with improvement in renal function [9, 10] . In addition, apolipoprotein L1 gene (APOL1) variants have been described as important genetic risk factors for the progression of chronic kidney disease (CKD) amongst African Americans [11, 12] .
Patients with established septic shock present with low HDL levels [13, 14] , and low HDL levels during sepsis are associated with adverse clinical outcomes such as greater ICU length of stay, greater hospital acquired infection rates and increased mortality rates [15, 16] .
Low levels of HDL were associated with both higher estimated glomerular filtration rate (eGFR) [17] and lower eGFR [18] in two different populations. It is not known whether HDL levels at presentation of sepsis have a role in sepsis-associated acute kidney injury (AKI) development or long-term decreased eGFR after sepsis. Therefore, our aim was to investigate the association between HDL levels during sepsis and the frequencies of sepsisassociated AKI, decreased eGFR from 3 months to 2 years postdischarge and/or all-cause mortality within 2 years from sepsis admission.
Materials and methods

Patients and study design
In this observational cohort study, a data set of 200 patients admitted to the Emergency Department (ED) at St. Paul's Hospital (SPH), Vancouver, Canada, from January 2011 to July 2013, was analysed. Patient inclusion criteria were the activation of the Institutional Sepsis Protocol by the attending physician, which requires the presence of a clinically defined infection and at least two of the following: (i) temperature >38°C or <36°C; (ii) heart rate >90 beats per minute; (iii) white blood cell count >12 000 per mm 3 or <4000 per mm 3 . Study identification numbers were assigned to the secured enrolment forms, and clinical data were stored in an ORACLE-based database on a firewalled, RSS-encrypted server at SPH. Patients with previous CKD at the time of the sepsis protocol activation were excluded from the analysis.
Blood collection and lipid measurements
A 6-mL EDTA tube of blood was collected at the time of the first clinical blood draw at the ED. Blood was spun at 1800 g for 12 min, and plasma was aliquoted and stored at -80°C until processing. Total cholesterol and HDL were measured in plasma on the SPH clinical laboratory's ADVIA 1800 Chemistry System (Siemens, Richmond, Canada). Non-HDL was calculated by subtracting HDL from total cholesterol. To assess HDL measurements collected previously to the sepsis event, provincial health records of all patients were reviewed and those with presepsis HDL measurements were then used for the determination of the difference between presepsis HDL and sepsis admission HDL.
AKI and long-term decreased eGFR
Acute kidney injury was defined and classified according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines [19] into stages 1-3. Patients were also categorized into two groups: noclinically significant AKI (patients with no sepsisassociated AKI and KDIGO stage 1) and clinically significant AKI (patients with sepsis-associated KDIGO 2 and 3).
For the determination of long-term decreased eGFR, patients were followed by reviewing provincial health records for all plasma creatinine concentration measurements during sepsis hospitalization and from 3 months up to 2 years following their initial enrolment. The most recent creatinine level of each patient was used for the estimation of the occurrence of decreased eGFR. Estimated glomerular filtration rate was determined by the Modification of Diet in Renal Disease (MDRD) equation [20] ) and decreased eGFR (eGFR <60 mL min À1 per 1.73 m 2 ).
Composite outcome (death or long-term decreased eGFR)
Death and decreased eGFR are competing events [21] in patients with septic shock (i.e. those with decreased eGFR are more likely to die) both during admission and postdischarge. To account for this statistically, we created a composite end-point of death or progression to decreased eGFR as we followed patients for 2 years following the index admission. Provincial records were reviewed, and patients who had experienced any one of the events aforementioned were considered to have experienced this composite outcome.
Renal function over time
We evaluated kidney function at five different timepoints: at admission, from day 1 (24 h from admission) to day 28 (in which we considered the worst measurement in our analysis), from 3 to 6 months, from 6 to 12 months and from 1 to 2 years after admission. In the first 28 days (2 initial time-points), we used creatinine measurements for renal function determination, and for the remaining ones, we used eGFR calculations.
Statistical analysis
Results are expressed as mean AE standard deviation for continuous variables and absolute number (%) for categorical variables. The KolmogorovSmirnov test was used to determine whether HDL, creatinine and eGFR levels were normally distributed.
The relationship between sensitivity and specificity was illustrated using a receiver operator characteristic curve for sepsis-associated AKI, and the median value for baseline HDL (33.06 mg dL
À1
) was used as the cut-off to dichotomize the patients into lower (baseline HDL <33.06 mg dL
) and higher (baseline HDL ≥ 33.06 mg dL À1 ) HDL groups. This value (33.06 mg dL
) was associated with sensitivity and specificity of 76% and 60% for AKI KDIGO and was used as the cut-off for all analysis in the present study.
We tested for association between baseline characteristics at hospital admission and the development of sepsis-associated AKI, decreased eGFR postdischarge or the composite outcome using the Chi-square test for dichotomous variables and Mann-Whitney U tests for continuous variables.
The mean (AE95% CI) values of creatinine were calculated in first 2 time-points and mean (AE95% CI) eGFR for the remaining 3 time-points. For a simplified analysis, the proportion of patients with decreased renal function was evaluated using eGFR in all time-points. Both measurements (the mean creatinine or eGFR and the proportion of decreased eGFR) were compared between the two HDL groups. Specifically for this analysis, we used the Last-Observation-Carried-Forward method for patients with missing data [22] .
We performed multivariate logistic regression to identify independent predictors for sepsis-associated AKI and long-term decreased eGFR. Sepsis-associated AKI development was analysed as a binary variable (clinically significant AKI or noclinically significant AKI) to identify risk factors using logistic regression. To estimate the probability of occurrence of the composite outcome, a timeto-event curve was performed. Event time was defined as the date of death or first detection of decreased eGFR (calculated through creatinine measurements). To analyse the effect of several variables for the event of interest, a Cox regression model was performed.
The multivariate models (for both logistic regression and Cox regression analyses) included variables based on univariate association at P < 0.1 and/or biological plausibility for the outcome of interest. To investigate any possible differential effect of HDL levels by statins, we also included an interaction term in our multivariate models between HDL group and statin use.
All analyses were performed using SPSS Statistics version 23.0 for Windows (IBM Corp., Armonk, NY, USA). Statistical significance was claimed when two-sided P values were smaller than 0.05.
Results
Participants
From the initial 200 patients, a total of 180 were analysed. Presepsis HDL measurements were available in 69 patients. The average period of time (mean AE SD) between presepsis HDL measurements and sepsis event was 15.5 AE 17.6 months. Patients with prior CKD according to KDIGO [23] were excluded from the analysis. Plasma HDL and total cholesterol were measured in all patients. Postdischarge creatinine levels were available in 115 patients for the determination of eGFR ( Fig. 1 ). Baseline characteristics of HDL groups (lower and higher) are presented in Table 1 . Previous use of statins and vasopressor use were negatively associated with plasma HDL levels. Patients from the lower HDL group had higher APACHE II score, creatinine, and white blood count measurements, and lower haemoglobin levels compared to patients from the higher HDL group (Table 1) .
Presepsis HDL and the sepsis-induced decline in HDL
HDL levels taken prior to the acute sepsis averaged 46.89 AE 15.88 mg dL À1 whilst patients at presentation to the ED had a decline of 13.06 AE 19.71 mg dL À1 , a mean drop of 28%. This suggests that low HDL level was not a risk factor to develop serious infection, but rather dropped acutely as infection became severe sepsis.
Occurrence of AKI and long-term decreased eGFR
Patients from the lower HDL group had significantly decreased renal function (creatinine and eGFR) at all time-points in comparison with patients with higher HDL levels (P < 0.05, Fig. 2a,b) . Additionally, the lower HDL group also presented with a significantly greater frequency of eGFR <60 mL min À1 per 1.73 m 2 at all time-points (P < 0.05), except the one between 3 and 6 months from sepsis hospitalization (P = 0.069) (Fig. 2c,d ). Fifty-one patients from a total of 180 (28.3%) developed clinically significant sepsis-associated AKI, which was less frequently observed in patients from the higher HDL group in comparison with lower HDL group [12/90 (13.3%) vs. 39/90 (43.3%), P < 0.001] (Fig. 3a) . Decreased eGFR within the 3-month to 2-year observation period after sepsis was found in 35/115 patents (30.4%), 101 (87.8%) of whom had prior AKI. Eleven of these patients (19.3%) belonged to the higher baseline HDL group, whilst 24 (41.4%) to the lower HDL group (P = 0.018) (Fig. 3b ).
HDL and risk of sepsis-associated AKI
Baseline HDL was significantly associated with the occurrence of sepsis-associated AKI. Each decrement in HDL was directly associated with a higher stage of AKI. HDL levels (mean AE SD) at admission were, respectively, 42. ; and 23.8 AE 15.7 mg dL À1 in patients with no AKI, AKI KDIGO 1, AKI KDIGO 2 and AKI KDIGO 3 (P < 0.001). HDL lower than the median at admission was an independent predictor for the development of stage 2 or stage 3 sepsis-associated AKI. The odds ratio (OR) for clinically significant AKI was 2.80 (95% CI 1.08-7.25, P = 0.033) in the lower baseline HDL group, after adjustment for age, gender, vasopressor use, hyperlactatemia >4 mmol L
À1
, APACHE II score and statin use. The interaction term between HDL groups and statins use was not statistically significant (P = 0.193). Baseline lactate level >4 mmol L À1 and APACHE II score were also associated with increased risk of AKI (OR 3.62, 95% CI 1.10 -11.90, P = 0.034 and OR 1.19, 95% CI 1.09-1.31, P < 0.001) ( Table 2 ).
HDL and risk of long-term decreased eGFR
A low HDL at admission was independently associated with the subsequent increased risk of longterm decreased eGFR following sepsis, after adjustment for age, gender, hypertension, diabetes mellitus, clinically significant sepsis-associated AKI, APACHE II score and statin use (Table 3) (P = 0.008). The interaction term between HDL groups and statin use was not statistically significant (P = 0.150). The OR for long-term decreased eGFR was higher in older patients and lower in men (OR = 1.06, 95% CI 1.01-1.11, P = 0.008; and OR = 0.315, 95% CI 0.106-0.935, P = 0.037, respectively).
Two-year follow-up: death or decreased eGFR according to presenting HDL
A higher proportion of patients died or progressed to decreased eGFR in the lower HDL group in comparison with patients from the higher HDL group [43/75 (57.3%) vs. 24/66 (36.4%), P = 0.020]. Baseline HDL levels below median were independently associated with increased probability of death (as a single outcome) and death or decreased eGFR (as a composite outcome) within 2 years of sepsis. There were 67 events related to the composite outcome (39 deaths and 28 decreased eGFR) during the follow-up period. The probability of death was 27.8% in the lower HDL group and 15.6% in the higher HDL group (P = 0.038), and the probability of the composite outcome was 57.3% in the lower HDL group and 36.4% in the higher HDL group (P = 0.013, Fig. 4 ). Cox regression analysis showed that lower levels of HDL at admission were independently associated with increased HR for the composite outcome along with female gender, higher APACHE II score and baseline lactate level >4 mmol L À1 . The HR for the composite outcome in the lower HDL group was 2.20 (95% CI 1.06-4.56, P = 0.033) ( Table 4 ). The interaction term between HDL groups and statin use was not statistically significant (P = 0.798).
Discussion
In the present study, we found that low plasma HDL in patients with very early sepsis presenting to the ED was highly associated with subsequent sepsis-associated AKI, long-term decreased eGFR and/or all-cause mortality within 2 years from sepsis.
Low levels of HDL have been associated with poor short-term outcomes (i.e. higher mortality rates [24] , organ failure development [25] and greater length of ICU stay [15] ) in patients with established septic shock [15, 24] and other acute disorders, such as pancreatitis [25] and burn-injured patients [26] . However, very few studies have investigated the relationship between HDL at presentation and the development of sepsis-associated AKI [9, 27] , nor have the factors involved in decreased eGFR after an episode of sepsis been completely elucidated. Abnormally low HDL (normal ≥ 40 mg dL À1 ) as a risk factor for both acute and CKDs is plausible biologically given HDL's ability to attenuate inflammation and kidney injury [4, 5, 9, 10] . Here, we expand this biological observation to find both worse short-term and long-term renal outcomes associated with low levels of HDL upon presentation for sepsis. 26 .9%. *P < 0.05 between HDL groups; **P < 0.001 between HDL groups. There were no differences in the proportion of patients with decreased eGFR in the period between 3 and 6 months (P = 0.069).
It appears that the level of HDL represents a continuous risk of renal injury, rather than a threshold effect. This hypothesis is corroborated by our findings, as we observed a significant gap in the mean value for each creatinine or eGFR measurements between the two HDL groups (Fig. 2a,b) , and a greater proportion of patients with decreased eGFR were from the lower HDL group (Fig. 2c,d) . Further, in an additional analysis, baseline HDL and creatinine levels showed an AUC for the occurrence of sepsis-associated AKI KDIGO 2 and 3 of 0.754 (P < 0.001) and 0.726 (P < 0.001), respectively. Interestingly, after combining HDL to creatinine at sepsis admission, the AUC increased to 0.847 and this increment was statistically significant when compared to single measurements of either HDL or creatinine levels.
The risk of sepsis-associated AKI was increased 2.8-fold in patients with HDL levels <33.06 mg dL
À1
. Surprisingly, this was a stronger risk factor than shock requiring vasopressors. Indeed, an HDL level <33.06 mg dL À1 was comparable to other factors highly associated with organ dysfunction(s) in sepsis, such as hyperlactatemia >4 mmol L À1 and an elevated APACHE II score (Table 2) [28, 29] .
The pathophysiology of sepsis-associated AKI involves adhesion of leucocytes by the activation of immune response and the subsequent release of cytokines, chemokines, reactive oxygen species, nitrogen oxygen species (RNS), cell cycle arrest, cellular oxidative stress and renal cell apoptosis [30] . HDL has beneficial effects in sepsis including neutralization of endotoxins [1] , antioxidant properties (mainly related to paraoxonase 1 -PON1) [31] , anti-apoptotic [6] and anti-thrombotic activity [7] . ApoA-I is the major apolipoprotein present in HDL, responsible for many of its anti-inflammatory effects [31] . The use of the synthetic ApoA-I mimetic peptide 4F has been studied in experimental animal models of sepsis and has been associated with higher survival rates [10] and decreased organ injury [9] . Some beneficial properties associated with ApoA-I mimetic peptides are downregulation of NF-jB [32] , suppression of cell adhesion molecules [32] , induction of nitric oxide synthase [33] and attenuation of kidney injury, heart injury and endothelial dysfunction [9] . Moreira et al. [9] found that the ApoA-I mimetic peptide 4F treatment decreased the expression of P-selectin in kidney tissue, decreased renal tubular injury, and reversed sepsis-induced downregulation of Slit2 and Robo4, both proteins involved in the maintenance of the endothelial barrier integrity. The purported protective mechanism of synthetic ApoA-I mimetic peptide 4F could be the attenuation of microvascular endothelial injury and hence, decreased fluid accumulation in the renal parenchyma and interstitium, with consequent lower impairment of microvascular renal perfusion and organ dysfunction [9] .
Taken together, we suggest that patients with low HDL levels suffer an attenuation of the aforementioned beneficial properties related to HDL (and ApoA-I) and therefore are more prone to poor outcomes related to sepsis, such as AKI. Perhaps, a higher HDL mitigates oxidative injury (through increased PON1 activity), inflammation (through greater endotoxin neutralization), endothelial damage, apoptosis and thrombotic events; all factors associated with AKI development in sepsis.
Chronically low HDL levels are associated with progression of CKD in patients with HIV [34] and patients with type 2 diabetes [35, 36] . Similar results were demonstrated in two epidemiological studies that evaluated the risk factors for the development of kidney disease. Schaeffner et al. [37] prospectively analysed 4483 healthy men and found that low HDL levels (<40 mg dL
) were significantly associated with an increase in the risk of developing renal dysfunction. Obermayr et al. [38] showed that a decrease by 10 mg dL À1 of HDL had an OR of 1.12 (95% C.I. 1.07-1.17) for the development of new-onset kidney disease in a prospective analysis of 17 375 healthy volunteers. In this manuscript, we show for the first time that an acute event (sepsis) appears to rapidly lower HDL and that this low HDL is associated with higher risk of decreased eGFR up to 2 years after sepsis (Table 3) . Additionally, patients in the lower HDL group were shown to have an approximately 5.5-fold increased risk of long-term decreased eGFR after adjustments for well-known factors associated with decreased renal function, such as hypertension [39] and diabetes mellitus [40] . Surprisingly, low HDL at presentation for sepsis represented a stronger risk factor for decreased eGFR following sepsis than the presence of clinically significant sepsis-associated AKI. This lack of association between AKI and decreased eGFR may be explained by the unique conditions found during severe sepsis. For instance, factors known to contribute to renal impairment, such as genetic variants [11, 12] and the presence of metabolic syndrome [41, 42] , may have overwhelmed the effects of AKI. A second possibility is that standardized aggressive resuscitation of sepsis includes reversal of AKI as an end-point, thus those with AKI are fluid-resuscitated most aggressively. This may reduce the long-term burden of CKD. Thirdly, our study excluded patients with CKD, the most important risk factor for acute kidney injury [42, 43] which may have resulted in lower severity and duration of sepsis-associated AKI in this cohort. This is suggested by the fact that 3.4% of our patients needed renal replacement therapy (representing 24% of those classified as KDIGO 3), which is lower than previously reported [44] . Taken together, these effects during acute sepsis suggest that there remains uncertainty as to whether sepsis-associated AKI is a major predictor of long-term renal function [45] . This effect was also not related to statin use, which itself was also not associated with higher risk for long-term decreased eGFR in our cohort, in agreement with a recent meta-analysis which did not find an association between statin use and progression of kidney disease [46] .
Prior studies postulated that the mechanism through which low HDL levels were associated with decreased renal function was through the coexistent high levels of non-HDL cholesterol [34] [35] [36] [37] . Increased non-HDL cholesterol may facilitate intra-renal arteriosclerosis [34] , microalbuminuria [35, 36] and lipid-induced glomerular toxicity [47] , precipitating renal dysfunction. In contrast, patients with decreased eGFR from our cohort showed lower levels of non-HDL (mean AE SD) when compared to patients with no decreased eGFR, although this difference was not statistically significant (74.7 AE 32.6 mg dL À1 vs. 86.7 AE 39.7 mg dL À1 , P = 0.111, data not shown). These discrepant findings might be explained by the fact that lipids were measured during sepsis, a condition associated with generalized hypocholesterolemia [48] , and not only low HDL levels. Therefore, the concept that decreased eGFR may occur due to increased arteriosclerosis caused by non-HDL cholesterol fractions cannot be applied in our cohort. Moreover, prior studies had longer follow-up and much greater sample size, and lipid measurements were taken during a 'nondisease state'.
Low levels of HDL have been shown to be associated with higher short-term mortality rates in sepsis [15, 24, 49] . We extended this observation when we analysed the association between HDL levels at sepsis presentation with the composite outcome of death or decreased eGFR. We used a composite end-point both to control for the effects of HDL in patients who died (and thus did not have the 'chance' of developing renal injury) and to provide a more comprehensive analysis of the effects of HDL on end-points related to both morbidity and mortality simultaneously. Lower baseline HDL was associated with increased HR for the composite outcome, having the highest risk for this outcome when compared to variables associated with short-term outcome (e.g. APACHE II and hyperlactatemia), and other variables such as the presence of sepsis-associated AKI (KDIGO 2 and 3), hypertension and older age (Table 4 ).
The strengths of the present study include the analysis of patients with early sepsis in the ED who were at risk of progressing to acute kidney injury, the association between HDL levels very early in sepsis with AKI and decreased eGFR risk over 2 years, and the persistent findings even after adjustment for confounding factors that could contribute to AKI and decline in renal function.
Our study had several limitations. First, our sample size was relatively small. Secondly, 65 patients had missing data for eGFR calculation, which could modify the incidence of long-term decreased eGFR. However, 40% of these patients (N = 26) were lost due to death (22 within 90 days and 4 from 90 days to 2 years). In addition, all baseline characteristics in the patients with missing data were similar when compared to patients who had follow-up data for eGFR calculation, except for the frequency of previous use of statins, which was higher in the latter group. We believe that the risk of bias associated with this difference is minor because we adjusted all our regression models for this specific variable and included additional interaction terms between statins and HDL levels. Thirdly, we could not use HDL as a continuous variable for all our outcomes because of a nonlinear relation between HDL and long-term decreased eGFR. Additionally, we did not use the 'normal' HDL as our cut-off (≥40 mg dL À1 in healthy conditions), because most of our patients had in fact 'abnormal' concentrations of HDL and all of them were not healthy. Finally, this is a single-centre observational cohort study of associations and so cannot prove cause and effect between HDL levels and renal disease in sepsis. More studies are needed to replicate and/or validate our findings, in independent cohorts from other countries or regions. However, it is hypothesis-generating for potential causal mechanisms for HDL and the development of acute or long-term decreased eGFR.
Conclusion
In this cohort of patients with septic shock, a low baseline HDL level (<33.06 mg dL
À1
) very early in sepsis was independently associated with increased risk of sepsis-associated AKI, decreased eGFR postdischarge (3 months to 2 years) or allcause 2-year mortality after sepsis. HDL's effect size surpassed well-known risk factors such as vasopressor use for sepsis-associated AKI and was surprisingly a stronger predictor for a long-term decline in eGFR than sepsis-related AKI or chronic hypertension. These data suggest that HDL could be a biomarker in early sepsis for risk of sepsisassociated AKI and/or long-term renal dysfunction after sepsis, with future studies still necessary to better elucidate the mechanisms of these associations.
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